Related CLVSClovis Oncology Could Pass $100 By Year-End: Here’s WhyClovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLCClovis Oncology: Don’t Discount Rociletinib’s Chances Against AZD9291(Seeking Alpha)Related EPZMBenzinga’s Top DowngradesH.C. Wainwright Destroys Epizyme Price Target, Sees ‘No Material Value Drivers’A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts […]
Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
Biotech Indices Can’t Break Through Triple Top
IBB at $365, XBI at $239
Red and green day
Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers.
First look at Rayno Biopharmaceutical Portfolio stocks:
Our big mover […]